Filter by: Subject

Filter by: Subject

Results Per Page:

South Africa (SA) (3)
Treatment (3)
Pharmacogenomics (2)
Acquired immune deficiency syndrome (AIDS) (1)
Activity score (1)
Activity score system (1)
Acute myeloid leukemia (AML) (1)
Adult patients (1)
Adverse drug reaction (1)
Adverse drug reactions (1)
Adverse drug reactions (ADRs) (1)
African populations (1)
Amitriptyline (1)
Binding protein-α (C/EBPα) (1)
Biological promise (1)
Caucasian populations (1)
Clinical Pharmacogenetics Implementation Consortium (CPIC) (1)
Commercialisation (1)
Communicable disease (1)
CYP2C19 (1)
CYP2D6 (1)
CYP450 (1)
Cystic fibrosis (CF) (1)
Cytogenetics (1)
Demethylation (1)
Developing world (1)
Diabetic neuropathy (1)
Diagnose (1)
Diagnosed fatal monogenic disorders (1)
Disease (1)
Drug metabolism (1)
Drug reactions (1)
Genotype-phenotype correlation (1)
Global precision medicine (1)
Hematopoietic stem cell transplantation (HSCT) (1)
Hematopoietic stem cells (HSCs) (1)
Hepatotoxicity (1)
Higher education institutions (1)
HIV/AIDS (1)
Human immunodeficiency virus (HIV) (1)
Indomethacin (1)
Infectious disease (1)
Infectious diseases (1)
Intellectual property (1)
Intellectual property -- South Africa (1)
Inter-ethnic variability (1)
Legal consequences (1)
Management (1)
Misconceptions (1)
Mortality (1)
Myeloid lineage (1)
Neurotoxicity (1)
Non-communicable diseases (NCDs) (1)
Nucleophosmin mutations (1)
Oomeprazole (1)
Pain (1)
Patients (1)
Pharmacogenetics (1)
Public umbilical cord blood bank (1)
Rats (1)
Science councils (1)
South Africa (1)
Stem cell therapy (1)
Sub-Saharan Africa (1)
Technology transfer -- South Africa (1)
Technology transfer offices (1)
UCB industry (1)
Umbilical cord blood (UCB) (1)
University entrepreneurship (1)